Publication

De novo development of proteolytically resistant therapeutic peptides for oral administration

Related publications (45)

About
Privacy
Disclaimer

Graph Chatbot

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

De novo development of proteolytically resistant therapeutic peptides for oral administration

Graph Chatbot

Chat with Graph Search

Cyclic peptide FXII inhibitor provides safe anticoagulation in a thrombosis model and in artificial lungs

Tissue Factor-Independent Coagulation Correlates with Clinical Phenotype in Factor XI Deficiency and Replacement Therapy

Development of cyclic peptide inhibitors of coagulation factor XIa for safer anticoagulation

Synthesis of DNA‐encoded disulfide‐ and thioether‐cyclized peptides

From Patients to Platelets and Back Again: Pharmacological Approaches to Glycoprotein VI, a Thrilling Antithrombotic Target with Minor Bleeding Risks

Development of cyclic peptide inhibitors of coagulation factor XII and matrix metalloproteinase 2

Anatomy and Physiology of the Digestive Tract of Drosophila melanogaster

Absence of specific alternatively spliced exon of CD44 in macrophages prevents colitis

Development of an albumin-binding ligand for prolonging the plasma half-life of peptide therapeutics

Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides